Topic: Research News

A new study found that semaglutide, a medication for type 2 diabetes, may also help prevent bone fractures. Researchers compared it to other weight-loss medications and found fewer fractures with semaglutide.

In a recent study, scientists discovered that semaglutide (Ozempic) might have an unexpected benefit for people with type 2 diabetes. They found that patients taking this medication experienced not only greater weight loss but also fewer bone fractures compared to those using other anti-obesity treatments.

The study was presented at the Endocrine Society's annual meeting in Chicago, Illinois. Researchers from Stanford University Medical Center in Palo Alto, California, led by Jairo Noreña, M.D., conducted the study.

Semaglutide belongs to a class of medications called glucagon-like peptide-1 receptor agonists (GLP-1s). These medications are commonly prescribed to treat obesity and type 2 diabetes. Earlier research raised concerns that rapid weight loss associated with GLP-1 medications may contribute to bone thinning and increase fracture risk.

The researchers analyzed data from over 59,000 patients treated at U.S. community hospitals and academic medical centers between January 2016 and December 2023. They found that patients taking semaglutide experienced a larger reduction in body mass index (BMI) than those in the comparison group. Additionally, they recorded fewer fractures among semaglutide users.

The study's findings suggest that semaglutide may offer a protective effect on bone health, but additional studies are needed to confirm this association.

In an interview, Jairo Noreña said,

Implications

A new study found that semaglutide, a medication for type 2 diabetes, may also help prevent bone fractures. Researchers compared it to other weight-loss medications and found fewer fractures with semaglutide.